An interventional study of Blood sampling and urine sampling in Pneumonia, Pneumocystis, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Other
This study aims to evaluate specialized proresolving mediators (SPM) concentrations for the first time in subjects infected with Pneumocystis jirovecii. SPM will be measured in blood and urine in patients with favourable or unfavourable outcome of Pneumocystis pneumonia and in patients colonized by Pneumocystis jirovecii. The hypothesis is that low levels of SPM in the blood could be predictive of a negative outcome of pneumocystosis.
Pneumocystis pneumonia is a severe fungal disease threatening immunosuppressed subjects such as patients suffering from AIDS, oncohematological diseases or solid organ transplanted patients. The disease is characterized by an important inflammation in the infected lungs which is mainly responsible for lungs lesions. Despite an adequate treatment introduction, mortality is still around 20% which can not be explained by a treatment resistance. Specialized proresolving mediators (SPM), including lipoxins, maresins, protectins and resolvins, are newly described molecules implicated in the active process of inflammation resolution. The investigators hypothesis in this study is that high levels of SPM could be predictive of a good resolution of the harmful inflammation, thus a good evolution of the disease, in adequate pneumocystosis therapy conditions. On the contrary, low levels of SPM could be predictive of an unfavourable outcome despite a treatment targeting Pneumocystis jirovecii
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
This study's enrollment of 66 is below the median of 106 across 1,247 interventional studies indexed under Pneumonia.
Browse Pneumonia studies →University Hospital, Toulouse is the lead sponsor of 794 studies on the registry; 214 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients with a favourable pneumocystosis outcome
Other: Blood sampling · Other: urine sampling
patients with unfavourable pneumocystosis outcome
Other: Blood sampling · Other: urine sampling
subject colonized by Pneumocystis jirovecii
Other: Blood sampling · Other: urine sampling
6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
2 urine sample (1 at J0 and 1 at J7)
14,15-DHET blood level at the inclusio
variation of 14,15-DHET blood level at inclusion between each group
Time frame: Day 0
14,15-DHET blood level
variation of 14,15-DHET blood level at day 7 between each group
Time frame: Day 7
14,15-DHET urine level
variation of 14,15-DHET urine level at inclusion ad day 7 between each group
Time frame: Day 0 and Day 7
Specialized Pro-Resolving Mediators in blood
Specialized Pro-Resolving Mediators in blood at inclusion and day 7 between each group
Time frame: Day 0 and Day 7
Specialized Pro-Resolving Mediators in urine
Specialized Pro-Resolving Mediators in urine at inclusion and day 7each between group
Time frame: Day 0 and Day 7
Expression levels of the SPM enzymes
Expression levels of the enzymes implicated in SPM synthesis and catabolism in blood at D0 and day 7
Time frame: Day 0 and day 7
Inflammatory blood profile
Inflammatory blood profile with composite criteria pro-inflammatory and anti-inflammatory cytokines levels measured by flow cytometry
Time frame: Day 0 and day 7
Immune cells profile
immune cell proportions in blood measured by flow cytometry
Time frame: Day 0 and day 7
Plan to share: No
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse